Bristol Pays $85 Million Upfront To Acquire Rheumatoid Arthritis Compound From Alder
This article was originally published in The Pink Sheet Daily
The deal also requires Bristol to make an equity investment of up to $20 million should Alder go public.
You may also be interested in...
Financings Of The Fortnight: Thiel Looks To Bridge The Pre-Venture Capital Funding Gap For Biotech
Plus news on recent financing activity by Alcresta, Alder Biopharmaceuticals, H.I.G Capital and Supernus Pharmaceuticals.
Hoping Drugs Take Root, Alder Raises $38 Million Round
The Bothell, Wash.-based antibody developer will study a Phase II interleukin-6 inhibitor in cancer indications, and will bring a new migraine drug into the clinic. The IL-6 drug is already partnered with BMS in a lucrative deal for autoimmune indications.
Biologics Swing For The Fences: Payer Perspectives On Antibodies In Primary Care
Companies with large-molecule expertise increasingly are eyeing primary care markets, confident that improvements in safety and efficacy will make them competitive with oral standards of care.